DOI: 10.1055/s-00050348

Indian Journal of Medical and Paediatric Oncology

LinksSchließen

Referenz

Ruhlmann CH, Christensen TB, Dohn LH, Paludan M, Rønnengart E, Halekoh U. et al.
Efficacy and safety of fosaprepitant for the prevention of nausea and emesis during 5 weeks of chemoradiotherapy for cervical cancer (the GAND-emesis study): A multinational, randomised, placebo-controlled, double-blind, phase 3 trial.

Lancet Oncol 2016;
17: 509-18

Bibliographische Angaben herunterladen

Aufrufen in:
Aufrufen in: